Anew Medical Inc. - רווח תפעולי לפני ניכוי פחת WENA

Anew Medical, Inc. (WENA) is developing gene therapies to combat ALS and Alzheimer's disease. The market's immense potential is driven by a shortage of effective medications. Trial logistics have been optimized through a laboratory network to protect margins. On GURU.Markets, the EBITDA level demonstrates the model's viability, with the metric value standing at .

Effective delegation of gene therapy development to external contractors allows Anew Medical, Inc. (WENA) to optimize costs while maintaining full control over intellectual property. The EBITDA_Co trend on this chart reflects the actual cash flow from core operations before taxes and depreciation, enabling investors to assess the business's fundamental solvency and the asset's resilience regardless of accounting adjustments.